Ahmed Mohammad Mohi Eldin Ali <br/><br/>
Treatment tailored therapy of diffuse large B-cell non hodgkin's lymphoma /  
 تحديد طريقة علاج حالات أورام الغدد الليمفاوية غير الهودجكن ذات الخلايا الكبيرة حسب كل حالة مرضية 
Ahmed Mohammad Mohi Eldin Ali ; Supervised Hussain Mostafa Khaled , Nadia Mahmoud Mokhtar , Foaad Mohammad AbuTaleb 
 - Cairo :   Ahmed Mohammad Mohi Eldin Ali ,   2012 
 - 175 P. :   charts ;   25cm 
<br/><br/>Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical 
<br/><br/> CD20-positive diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of new cases of lymphoma. DLBCL is a heterogeneous disease that includes at least two prognostically important subtypes (i.e. germinal center B-cell like [GCB] and non-germinal center B-cell like [non-GCB]). These subtypes initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>CD20-positive diffuse large B-cell lymphoma R-CHOP Rituximab